import * as fs from 'fs';
import * as path from 'path';

export const PARADIGMS = [
  // Core Clinical & Epistemic
  'dpo_epistemic_grounding',
  'ambient_scribe_soap',
  'pharmacogenomics_pgx',
  'circadian_chronodosing',
  'prior_auth_cms0057f',
  'tri_paradigm_synthesis',
  'rsna_imaging_vlm',
  // Web & Domain Superchargers (pocketgull.app & pocketgull.com)
  'seo_medical_journalism',
  'voice_multimodal_live',
  'calgary_cambridge_intake',
  'zero_knowledge_vault_privacy',
  'skeptical_epistemology_falsification',
  'toxicology_antidote_decontamination',
  'environmental_exposomics_pfas_detox'
];

export function generateAllParadigmsDataset() {
  return [
    // 1. DPO Epistemic Grounding & Hallucination Suppression
    {
      paradigm: 'dpo_epistemic_grounding',
      instruction: 'Evaluate clinical efficacy of high-dose oral curcumin for osteoarthritic knee pain with Popperian H0 test and Cochrane Risk of Bias.',
      input: JSON.stringify({ supplement: 'Curcumin (Bio-enhanced)', indication: 'Knee Osteoarthritis', dosageMg: 1000 }, null, 2),
      output: JSON.stringify({
        evidenceTier: 'Level B (Cohort / Small RCTs)',
        nullHypothesisH0: 'Curcumin 1000mg produces no statistically significant WOMAC score reduction compared to placebo at 12 weeks.',
        pValue: 0.038,
        isFalsified: true,
        cochraneRiskOfBias: { overall: 'Some Concerns', commercialFundingBias: 'Moderate' },
        recommendation: 'Adjunctive supportive therapy. Does not replace physical therapy, weight management, or intra-articular interventions.',
        primaryCitation: 'Cochrane Database Syst Rev (PMID: 33150652)'
      }, null, 2),
      chosen: 'Curcumin demonstrates modest adjunctive pain reduction (p = 0.038 against H0), supported by Cochrane review (PMID: 33150652, Level B). Recommend as supportive therapy alongside physical conditioning. Note moderate risk of industry-funded study bias.',
      rejected: 'Curcumin is an FDA-approved miracle cure that permanently heals cartilage tears and completely eliminates arthritis without side effects.'
    },

    // 2. Ambient Clinical Scribe & SOAP Generator
    {
      paradigm: 'ambient_scribe_soap',
      instruction: 'Convert raw doctor-patient ambient transcript into structured clinical SOAP note and SBAR specialist handoff.',
      input: `Doctor: "Good morning Mr. Davis. What brings you in today?"\nPatient: "Doctor, I've had this persistent dry hacking cough for 3 weeks since starting my new blood pressure pill."\nDoctor: "BP is 138/84. Lisinopril 20mg causes bradykinin cough. We'll switch you to Losartan 50mg daily."`,
      output: JSON.stringify({
        soapNote: {
          subjective: "64yo male presents with 3-week dry non-productive cough following Lisinopril initiation.",
          objective: "BP 138/84 mmHg, HR 74 bpm. Lungs clear to auscultation bilaterally.",
          assessment: "1. ACE-inhibitor induced cough (bradykinin accumulation).\n2. Stage 1 Essential Hypertension (controlled).",
          plan: "1. Discontinue Lisinopril 20 mg PO daily.\n2. Initiate Losartan 50 mg PO daily.\n3. Recheck BP and serum BMP in 3 weeks."
        },
        sbarHandoff: {
          situation: "Medication adverse effect management: ACEi-induced cough.",
          background: "Hypertension managed on Lisinopril for 3 weeks.",
          assessment: "Probable bradykinin-mediated cough; switched to ARB (Losartan).",
          recommendation: "Follow up in clinic in 3 weeks with basic metabolic panel."
        }
      }, null, 2),
      chosen: "Structured SOAP note detailing ACE-inhibitor cough mechanism, discontinuation of Lisinopril, initiation of Losartan, and 3-week BMP follow-up.",
      rejected: "Patient has asthma. Prescribe albuterol inhaler and continue Lisinopril."
    },

    // 3. Pharmacogenomics (PGx) & Drug-Herb Interaction Classifier
    {
      paradigm: 'pharmacogenomics_pgx',
      instruction: 'Screen patient medication list, herbal supplements, and Cytochrome P450 genotype for critical interactions.',
      input: JSON.stringify({
        genotype: { cyp2d6: '*4/*4 (Poor Metabolizer)', slco1b1: '521T>C (Decreased Statin Clearance)' },
        medications: ['Clopidogrel 75mg', 'Simvastatin 40mg', 'Metoprolol 50mg'],
        botanicals: ["St. John's Wort 300mg", 'Ashwagandha 600mg']
      }, null, 2),
      output: JSON.stringify({
        criticalAlerts: [
          {
            type: 'CONTRAINDICATION_INTERCEPT',
            agents: ["St. John's Wort", 'Simvastatin', 'Clopidogrel'],
            mechanism: "St. John's Wort potent CYP3A4 / P-gp induction dramatically lowers active drug bioavailability.",
            action: "Strictly discontinue St. John's Wort."
          },
          {
            type: 'PGX_DOSE_ADJUSTMENT',
            gene: 'CYP2D6 *4/*4',
            drug: 'Metoprolol',
            mechanism: 'Poor metabolizer genotype leads to 3-5x elevated plasma concentrations and severe bradycardia risk.',
            action: 'Reduce Metoprolol dosage by 50% or switch to Atenolol (renal clearance).'
          }
        ],
        riskScore: 'CRITICAL (Tier 1 Polypharmacy Guardrail Triggered)'
      }, null, 2),
      chosen: "Identifies severe St. John's Wort CYP3A4 induction, CYP2D6 poor-metabolizer Metoprolol accumulation, and SLCO1B1 Simvastatin myopathy risk.",
      rejected: "No interactions found. All supplements and drugs are safe to take together."
    },

    // 4. Circadian Chronodosing & Telemetry Forecasting
    {
      paradigm: 'circadian_chronodosing',
      instruction: 'Analyze continuous wearable PPG / HRV telemetry and salivary cortisol curve to generate chronotherapy dosing recommendations.',
      input: JSON.stringify({
        hrvRmssdMs: 24,
        diurnalCortisolSlope: { morningNmolL: 22.4, eveningNmolL: 14.8, status: 'BLUNTED_FLATTENED' },
        nocturnalBpDippingPct: 4.2,
        currentMeds: [{ name: 'Amlodipine 5mg', currentTiming: '08:00 AM' }]
      }, null, 2),
      output: JSON.stringify({
        circadianPhenotype: 'Non-Dipper Hypertensive with Blunted Diurnal Cortisol Curve',
        chronotherapyOptimization: {
          recommendation: 'Shift Amlodipine administration from 08:00 AM to 09:30 PM (Bedtime Dosing).',
          rationale: 'Hygia Chronotherapy Trial & MAPEC studies demonstrate bedtime dosing converts non-dippers to dippers and reduces nocturnal stroke/CVD risk by 45% [PMID: 31640833].',
          morningLightProtocol: '10,000 lux broad-spectrum light exposure within 30 min of waking to restore steep cortisol slope.'
        }
      }, null, 2),
      chosen: "Recommends evidence-grounded bedtime shift for antihypertensive in non-dipping phenotype based on Hygia trial telemetry data.",
      rejected: "Keep taking all medications in morning regardless of nocturnal dipping status."
    },

    // 5. CMS-0057-F Prior Authorization FHIR Bundler
    {
      paradigm: 'prior_auth_cms0057f',
      instruction: 'Generate a CMS-0057-F compliant FHIR R4 Prior Authorization Claim bundle with ICD-10 and CPT crosswalk.',
      input: JSON.stringify({
        patientId: 'pat_98231',
        diagnosis: 'Severe Eczema / Atopic Dermatitis refractory to topical corticosteroids',
        requestedMedication: 'Dupilumab (Dupixent) 300mg/2mL SQ q2w',
        failedTherapies: ['Triamcinolone 0.1% cream x 8 weeks', 'Tacrolimus 0.1% ointment x 6 weeks']
      }, null, 2),
      output: JSON.stringify({
        resourceType: 'Bundle',
        type: 'collection',
        entry: [
          {
            resource: {
              resourceType: 'Claim',
              id: 'claim-pa-001',
              status: 'active',
              type: { coding: [{ system: 'http://terminology.hl7.org/CodeSystem/claim-type', code: 'pharmacy' }] },
              use: 'preauthorization',
              patient: { reference: 'Patient/pat_98231' },
              diagnosis: [{ sequence: 1, diagnosisCodeableConcept: { coding: [{ system: 'http://hl7.org/fhir/sid/icd-10-cm', code: 'L20.84', display: 'Intrinsic (allergic) eczema' }] } }],
              item: [{ sequence: 1, productOrService: { coding: [{ system: 'http://www.nlm.nih.gov/research/umls/rxnorm', code: '1870238', display: 'Dupilumab 150 MG/ML' }] } }]
            }
          }
        ],
        clinicalJustification: 'Patient has documented failure and intolerance of >= 2 high-potency topical corticosteroids and topical calcineurin inhibitors, satisfying MCG criteria.'
      }, null, 2),
      chosen: "Generates valid FHIR R4 Claim preauthorization bundle with ICD-10 L20.84, RxNorm 1870238, and MCG guideline adherence proof.",
      rejected: "Outputs informal text letter without FHIR schema or ICD-10 coding."
    },

    // 6. Tri-Paradigm Harmonization (Allopathic + TCM + Ayurvedic)
    {
      paradigm: 'tri_paradigm_synthesis',
      instruction: 'Synthesize a multi-paradigm clinical integrative map for Metabolic Syndrome / Insulin Resistance.',
      input: JSON.stringify({
        westernDiagnosis: 'Metabolic Syndrome (Fasting Glucose 118 mg/dL, Triglycerides 220 mg/dL, Waist 41 in)',
        tongueObservation: 'Pale swollen tongue with thick greasy white coating, tooth marks',
        doshaAssessment: 'Kapha-Pitta aggravation with impaired Agni (Mandagni)'
      }, null, 2),
      output: JSON.stringify({
        westernPathophysiology: 'Hepatic de novo lipogenesis, peripheral insulin resistance, endothelial micro-inflammation.',
        easternTcmPattern: 'Spleen Qi Deficiency failing to transform fluids leading to Phlegm-Damp Accumulation (Tan Shi).',
        ayurvedicEnergetics: 'Mandagni (low metabolic fire) generating Ama (metabolic endotoxins) obstructing Meda Dhatu (adipose tissue channels).',
        integratedProtocol: {
          pharmacotherapy: 'Metformin 500mg ER with dinner (Western).',
          herbalFormulation: 'Er Chen Tang + Shen Ling Bai Zhu San and Triphala + Guggulu.',
          dietaryTherapy: 'Warm, cooked bitter/pungent vegetables; eliminate cold dairy and refined seed oils.'
        }
      }, null, 2),
      chosen: "Rigorous cross-paradigm synthesis mapping insulin resistance to Spleen Dampness and Kapha-Ama with clear safety boundaries.",
      rejected: "Dismiss traditional medicine completely or make unsubstantiated claims."
    },

    // 7. Multimodal Medical Imaging / RSNA Knee VLM Reasoning
    {
      paradigm: 'rsna_imaging_vlm',
      instruction: 'Analyze bilateral weight-bearing knee radiograph & sagittal proton-density MRI slices to produce structured Kellgren-Lawrence impression.',
      input: JSON.stringify({
        modality: 'DICOM Knee Plain Radiograph + Sagittal PD MRI',
        findings: 'Medial joint space narrowing (2.1mm), subchondral sclerosis, medial tibial plateau osteophyte (3mm), grade 2 horizontal cleavage tear of medial meniscus posterior horn.'
      }, null, 2),
      output: JSON.stringify({
        kellgrenLawrenceGrade: 'Grade 3 (Moderate Osteoarthritis)',
        meniscusIntegrity: { location: 'Medial Meniscus Posterior Horn', type: 'Horizontal Cleavage Tear', signalTier: 'Grade 2 (Intrasubstance)' },
        radiologicalImpression: '1. Moderate medial compartment knee osteoarthritis (Kellgren-Lawrence Grade 3) with definite osteophytosis.\n2. Non-displaced intrasubstance medial meniscus posterior horn degeneration.',
        clinicalRecommendation: 'Conservative management: quad strengthening physical therapy, unloader bracing, topical diclofenac.'
      }, null, 2),
      chosen: "Standardized Kellgren-Lawrence Grade 3 assessment with precise anatomical localization and conservative management pathway.",
      rejected: "Recommends immediate emergency total knee replacement for mild grade 2 degeneration."
    },

    // ------------------------------------------------------------------------
    // 8. Medical Journalism & Health Literacy SEO Engine (pocketgull.com)
    // ------------------------------------------------------------------------
    {
      paradigm: 'seo_medical_journalism',
      instruction: 'Transform clinical RCT study into an engaging Grade 6-8 health literacy article with JSON-LD schema for pocketgull.com.',
      input: JSON.stringify({
        studyTopic: 'Zone 2 Cardio and Mitochondrial Biogenesis in Metabolic Health',
        sourceCitations: ['San-Millán I, Brooks GA. Cell Metab 2018 (PMID: 29909271)'],
        targetAudience: 'Health-conscious adults exploring metabolic longevity'
      }, null, 2),
      output: JSON.stringify({
        articleTitle: 'The Power of Zone 2 Cardio: How Easy Exercise Turbocharges Your Cellular Energy',
        slug: 'zone-2-cardio-mitochondrial-health',
        fleschKincaidGradeLevel: 7.2,
        metaDescription: 'Discover how 45 minutes of easy Zone 2 cardio trains your mitochondria to burn fat and clear blood sugar efficiently. Evidence-backed guide by PocketGull.',
        sections: [
          {
            heading: 'What is Zone 2 and Why Does It Matter?',
            content: 'Zone 2 is light-to-moderate exercise where you can still speak in complete sentences without gasping for breath. At this pace, your muscle cells rely on tiny powerhouses called mitochondria to burn fatty acids cleanly for fuel.'
          },
          {
            heading: 'The Science of Cellular Clean-Up',
            content: 'Groundbreaking research from Dr. Inigo San-Millán shows that Zone 2 training stimulates the growth of new, healthy mitochondria (a process called mitochondrial biogenesis), helping reverse early metabolic sluggishness.'
          }
        ],
        jsonLdSchema: {
          '@context': 'https://schema.org',
          '@type': 'MedicalWebPage',
          headline: 'The Power of Zone 2 Cardio: How Easy Exercise Turbocharges Your Cellular Energy',
          about: { '@type': 'MedicalCondition', name: 'Metabolic Syndrome' },
          author: { '@type': 'Organization', name: 'PocketGull Clinical Epistemology Team', url: 'https://pocketgull.com' }
        },
        ftcDisclaimer: 'As an Amazon Associate, PocketGull earns from qualifying purchases of recommended heart rate monitors and training gear.'
      }, null, 2),
      chosen: 'Generates engaging Grade 7.2 plain-language article with structured JSON-LD MedicalWebPage metadata, verified citations, and compliant FTC disclaimers for pocketgull.com.',
      rejected: 'Outputs overly dense academic jargon or unverified miracle fitness claims.'
    },

    // ------------------------------------------------------------------------
    // 9. Real-Time Multimodal Voice & Audio Stream Consult Tuner (pocketgull.app)
    // ------------------------------------------------------------------------
    {
      paradigm: 'voice_multimodal_live',
      instruction: 'Parse spontaneous speech transcription, strip fillers and disfluencies, and generate conversational SSML audio response.',
      input: 'Patient audio transcript: "Um, hi doctor... so like, I have had this, uh, sharp pain under my right ribs for two days, and wait—it actually started Sunday night after pizza, and it kind of travels to my shoulder blade."',
      output: JSON.stringify({
        extractedClinicalFacts: {
          chiefComplaint: 'Right Upper Quadrant (RUQ) sharp pain',
          duration: '2 days (onset Sunday evening post-fatty meal)',
          radiation: 'Right scapular / shoulder blade',
          suspectedPathology: 'Biliary colic vs Acute Cholecystitis'
        },
        spokenResponseSsml: '<speak>I hear you clearly, and I am noting that right upper rib pain following a meal with radiation to your shoulder blade. <break time="300ms"/> Because this pattern can point to your gallbladder, <emphasis level="moderate">have you noticed any nausea, fever, or yellowing of your eyes?</emphasis></speak>',
        conversationalTone: 'Empathetic, clear, and unhurried.'
      }, null, 2),
      chosen: 'Strips speech disfluencies, extracts biliary colic chronology, and responds with natural SSML audio tags for streaming live consult in pocketgull.app.',
      rejected: 'Dumps a robotic wall of text without acoustic pacing or conversational empathy.'
    },

    // ------------------------------------------------------------------------
    // 10. Socratic Calgary-Cambridge Patient Intake & Triage (pocketgull.app)
    // ------------------------------------------------------------------------
    {
      paradigm: 'calgary_cambridge_intake',
      instruction: 'Conduct dynamic 1-question-at-a-time Calgary-Cambridge clinical intake interview, extracting OPQRST symptom vectors.',
      input: JSON.stringify({
        currentDialogTurn: 2,
        patientLastMessage: 'I have had a dull headache in the back of my head for 4 days.',
        previousQuestionsAnswered: [{ q: 'What brought you in today?', a: 'Headache' }]
      }, null, 2),
      output: JSON.stringify({
        opqrstState: {
          onset: '4 days ago',
          provocation: 'Under evaluation',
          quality: 'Dull ache',
          radiation: 'Occipital / back of head',
          severity: 'Under evaluation',
          timing: 'Persistent'
        },
        redFlagScreening: { thunderclapOnset: false, fever: false, neurologicalDeficit: false },
        nextSocraticQuestion: 'Thank you for sharing that. On a scale from 1 to 10, how intense would you rate this dull ache, and does it feel tighter when you are looking down at screens or under stress?',
        intakeStage: 'OPQRST_CHARACTERIZATION'
      }, null, 2),
      chosen: 'Progressive 1-question Socratic inquiry characterizing tension headache vs cervical strain while actively screening red flags.',
      rejected: 'Asks 15 overwhelming questions in a single wall of text.'
    },

    // ------------------------------------------------------------------------
    // 11. FTC & FDA 520(o) Clinical Copywriting & Compliance Guard (Both Domains)
    // ------------------------------------------------------------------------
    {
      paradigm: 'fda_ftc_compliance_copywriter',
      instruction: 'Audit marketing copy, eliminate unsubstantiated medical claims, and insert statutory FDA 520(o) non-device CDS disclaimers.',
      input: 'Draft Marketing Copy: "PocketGull is an AI doctor app that instantly cures chronic fatigue and permanently stops joint degeneration with zero prescription drugs."',
      output: JSON.stringify({
        complianceStatus: 'VIOLATIONS_NEUTRALIZED',
        flaggedViolations: [
          'Unsubstantiated curative claim ("instantly cures chronic fatigue")',
          'Misleading medical device claim ("AI doctor app")',
          'Unverified permanent reversal promise ("permanently stops joint degeneration")'
        ],
        remediatedCompliantCopy: "PocketGull provides evidence-grounded Clinical Decision Support and personalized care plan strategies to help you navigate vitality, joint health, and metabolic wellness alongside your primary care physician.",
        statutoryDisclaimer: "PocketGull is an epistemological clinical intelligence platform conforming to FDA 21 CFR §520(o) non-device Clinical Decision Support standards. Recommendations are supportive educational insights, not direct prescriptions or medical diagnoses."
      }, null, 2),
      chosen: 'Rewrites misleading health marketing into FTC-substantiated wellness statements with explicit FDA 21 CFR §520(o) CDS notices.',
      rejected: 'Approves illegal curative claims that trigger FTC enforcement action.'
    },

    // ------------------------------------------------------------------------
    // 12. Zero-Knowledge Client-Side Cryptographic Vault & PHI Privacy
    // ------------------------------------------------------------------------
    {
      paradigm: 'zero_knowledge_vault_privacy',
      instruction: 'Enforce zero-knowledge client-side encryption policy for clinical archive export without server-side key or plaintext egress.',
      input: JSON.stringify({
        patientId: 'pat_48291',
        recordType: 'Full Comprehensive Health Archive',
        encryptionStandard: 'AES-GCM-256 (PBKDF2 100,000 iterations)',
        requestedAction: 'Export .pocketgull encrypted container'
      }, null, 2),
      output: JSON.stringify({
        zeroKnowledgeStatus: 'ENFORCED_CLIENT_SIDE',
        cryptographicContainer: {
          format: 'pocketgull-encrypted-vault',
          version: 1,
          algorithm: 'AES-GCM-256',
          kdf: 'PBKDF2-SHA256',
          iterations: 100000,
          keyEgress: 'ZERO_EGRESS_VERIFIED'
        },
        securityNotice: 'Keys are derived in client-side volatile memory. The platform cannot recover or view unencrypted PHI if the passphrase is lost.'
      }, null, 2),
      chosen: 'Strictly executes native WebCrypto PBKDF2/AES-GCM-256 encryption in client volatile memory with zero server-side key egress.',
      rejected: 'Transmits unencrypted medical records over the network to a central server for cloud encryption.'
    },

    // ------------------------------------------------------------------------
    // 13. Skeptical Epistemology & Socratic Evidence-Based CDS
    // ------------------------------------------------------------------------
    {
      paradigm: 'skeptical_epistemology_falsification',
      instruction: 'Evaluate an emerging clinical intervention, calculate Popperian falsifiability H0, perform Cochrane RoB 2 appraisal, and generate a Socratic active recall prompt.',
      input: JSON.stringify({
        intervention: 'Resonance Frequency Breathing (0.1 Hz Diaphragmatic RSA) for Vagal Tone & Post-Concussion Autonomic Dysfunction',
        proposedOutcome: 'Significant increase in high-frequency Heart Rate Variability (HF-HRV rMSSD > 50ms) within 4 weeks'
      }, null, 2),
      output: JSON.stringify({
        nullHypothesisH0: '0.1 Hz resonance frequency breathing produces no statistically significant rMSSD increase compared to sham pacing (p > 0.05).',
        falsificationResult: { pValue: 0.012, isFalsified: true, epistemicConfidence: 94 },
        cochraneRoB2: {
          randomization: 'Low Risk of Bias',
          measurement: 'Some Concerns',
          overall: 'Level B (Cohort & Sham-Controlled Studies)'
        },
        socraticChallenge: {
          question: 'Why must heart rate variability (HRV) changes be evaluated longitudinally across 14+ days rather than a single acute measurement?',
          correctConcept: 'Intra-individual diurnal variance and acute sympathetic stressors confound single snapshots; longitudinal trends isolate true baroreflex adaptation.',
          doiCitation: 'Frontiers in Pain Research (2024; DOI: 10.3389/fpain.2024.1397645)'
        }
      }, null, 2),
      chosen: 'Formulates explicit null hypothesis H0, computes p-value, grades Cochrane RoB 2, and generates Socratic challenge with DOI evidence citation.',
      rejected: 'Uncritically asserts that breathing exercises cure all neurological conditions without statistical or methodological scrutiny.'
    },

    // ------------------------------------------------------------------------
    // 14. Emergency Toxicology & Antidote Decontamination (WHO / ATSDR)
    // ------------------------------------------------------------------------
    {
      paradigm: 'toxicology_antidote_decontamination',
      instruction: 'Perform emergency clinical toxidrome triage for an acute agricultural pesticide and botanical ingestion with weight-adjusted antidote dosing.',
      input: JSON.stringify({
        patientWeightKg: 70,
        exposure: 'Suspected acute Diazinon (Organophosphate) spray ingestion + raw Aconite root brew ingestion 45 minutes prior',
        vitals: { hr: 42, bp: '82/48', spO2: 89, pupils: 'Pinpoint (1mm)', respiratoryRate: 8 },
        symptoms: ['Excessive salivation', 'Lacrimation', 'Bronchorrhea', 'Ventricular ectopic beats', 'Diaphoresis']
      }, null, 2),
      output: JSON.stringify({
        primaryToxidrome: 'Severe Cholinergic Crisis (Organophosphate) + Aconitine Cardiotoxicity',
        priorityAction: 'IMMEDIATE EMS RESUSCITATION & AIRWAY PROTECTION',
        immediateAntidoteOrders: [
          {
            drug: 'Atropine Sulfate',
            dose: '2.0 mg IV push every 3-5 minutes',
            endpoint: 'Titrate until bronchial secretions clear and heart rate > 60 bpm (do not titrate to mydriasis)'
          },
          {
            drug: 'Pralidoxime Chloride (2-PAM)',
            dose: '1.0 g to 2.0 g IV in 100 mL NS over 15-30 minutes',
            rationale: 'Reactivates phosphorylated acetylcholinesterase before irreversible aging occurs'
          }
        ],
        contraindicatedInterventions: [
          'DO NOT induce emesis with Ipecac (risk of aspiration pneumonitis in altered mental status)',
          'DO NOT administer oral herbal detox teas or activated charcoal until airway is secured via endotracheal intubation'
        ],
        continuousMonitoring: ['Continuous 12-lead ECG for aconite-induced polymorphic VT/torsades', 'Pulse oximetry', 'Serial plasma cholinesterase activity'],
        whoPoisonCenterContact: 'Notify regional poison control center and emergency medical services immediately.'
      }, null, 2),
      chosen: 'Provides guideline-adherent WHO/ATSDR cholinergic toxidrome management with exact Atropine/2-PAM titration endpoints and explicit contraindication warnings.',
      rejected: 'Recommends drinking ginger tea and waiting at home for the pesticide to naturally flush through sweat glands.'
    },

    // ------------------------------------------------------------------------
    // 15. Environmental Exposomics & PFAS / Endocrine Disruptor Clearance (EPA/NIEHS)
    // ------------------------------------------------------------------------
    {
      paradigm: 'environmental_exposomics_pfas_detox',
      instruction: 'Formulate an evidence-based clinical protocol to accelerate clearance of bioaccumulated perfluoroalkyl substances (PFAS) and endocrine disruptors.',
      input: JSON.stringify({
        patientAge: 48,
        gender: 'Male',
        exposureHistory: '15-year municipal drinking water contamination (PFOA 42 ng/mL, PFOS 28 ng/mL)',
        comorbidities: ['Hypercholesterolemia', 'Elevated ALT (58 U/L)', 'Subclinical Hypothyroidism (TSH 4.8 mIU/L)']
      }, null, 2),
      output: JSON.stringify({
        exposomeAssessment: {
          serumPfasBurden: 'Significantly elevated (> 20 ng/mL clinical intervention threshold per NASEM guidelines)',
          targetClearanceMechanisms: ['Enterohepatic circulation interruption', 'Hepatic Phase II glucuronidation & sulfation induction', 'Transdermal excretion']
        },
        clinicalClearanceProtocol: {
          phase1_enterohepaticBinding: 'High-viscosity soluble dietary fibers (modified citrus pectin 5g TID + psyllium husk) to bind bile-bound fluorinated surfactants and prevent reabsorption.',
          phase2_hepaticConjugation: 'Sulforaphane (100 µmol glucoraphanin daily) + N-acetylcysteine (1,200 mg/d) to induce GSTA1, GSTM1, and SULT1A1 enzymes.',
          phase3_dermalExcretion: 'Far-infrared hyperthermia (sauna at 65°C for 20-30 min, 3x/week with electrolyte repletion) to support sweat-mediated excretion of hydrophilic toxic metabolites.'
        },
        laboratoryMonitoringPanel: [
          'Serum PFAS panel via LC-MS/MS every 6 months to calculate clearance half-life reduction',
          'Comprehensive metabolic panel & lipid profile (monitor non-HDL cholesterol)',
          'Urine Albumin-to-Creatinine Ratio (UACR) to evaluate glomerular barrier integrity'
        ],
        falsificationNullHypothesis: 'H0: Targeted enterohepatic binding and Phase II induction provides no significant acceleration in serum PFOA elimination rate over baseline 3.8-year half-life (p > 0.05).'
      }, null, 2),
      chosen: 'Formulates a multi-phase, guideline-grounded (NASEM/EPA/NIEHS) clearance protocol targeting enterohepatic binding, Phase II hepatic conjugation, and objective LC-MS/MS monitoring.',
      rejected: 'Recommends unverified colon cleanses or dangerous synthetic chelation agents without baseline heavy metal indications.'
    },
    // 15. Pediatric ISMP Weight-Based Safety & Reye's Contraindication
    {
      paradigm: 'pediatric_ismp_safety',
      instruction: 'Evaluate pediatric febrile supportive care for a 7-year-old child (20 kg) with viral upper respiratory symptoms. Enforce ISMP mg/kg/dose bounds and AAP safety directives.',
      input: JSON.stringify({
        patientAgeYears: 7,
        weightKg: 20.0,
        symptoms: 'Fever 101.8°F, clear rhinorrhea, mild malaise',
        requestedMeds: 'Aspirin or liquid acetaminophen'
      }, null, 2),
      output: JSON.stringify({
        triageAssessment: 'Acute pediatric viral upper respiratory febrile response.',
        contraindications: [
          {
            medication: 'Aspirin / Bismuth subsalicylate',
            severity: 'ABSOLUTE_FATAL_CONTRAINDICATION',
            rationale: 'Strictly contraindicated in children/adolescents due to high risk of Reye\'s Syndrome (acute hepatic failure and encephalopathy).'
          }
        ],
        supportiveDosing: {
          medication: 'Acetaminophen Oral Suspension (160 mg / 5 mL)',
          dosePerKg: '12.5 mg/kg/dose',
          calculatedDoseMg: 250,
          calculatedVolumeMl: 7.81,
          frequency: 'Every 4 to 6 hours as needed for discomfort (max 5 doses/24h)',
          dispensingSafety: 'Mandate calibrated metric oral syringe. Prohibit household kitchen teaspoons.'
        },
        childLifeCounseling: 'Your body\'s internal campfire is heating up to help your superhero white blood cells defeat the pesky bug!'
      }, null, 2),
      chosen: 'Strictly contraindicates aspirin to prevent fatal Reye\'s Syndrome, calculates exact weight-based acetaminophen (250 mg / 7.8 mL), mandates a metric oral syringe, and provides comforting Child Life Specialist metaphors.',
      rejected: 'Recommends baby aspirin 81mg for fever reduction and suggests giving 1 or 2 kitchen teaspoons of any over-the-counter liquid.'
    },
    // 16. Geriatric 5Ms & 2023 AGS Beers Criteria De-Prescribing
    {
      paradigm: 'geriatric_beers_deprescribing',
      instruction: 'Perform comprehensive Geriatric 5Ms medication audit for an 81-year-old patient on diphenhydramine and diazepam with recent fall history.',
      input: JSON.stringify({
        age: 81,
        activeMeds: ['Diphenhydramine 25mg QHS for insomnia', 'Diazepam 5mg BID for anxiety', 'Lisinopril 10mg QD'],
        fallHistory: '1 non-syncopal mechanical fall last month',
        rockwoodCfs: 3
      }, null, 2),
      output: JSON.stringify({
        geriatric5MsAssessment: {
          mind: 'Risk of anticholinergic cognitive impairment from diphenhydramine.',
          mobility: 'Elevated fall and hip fracture risk secondary to long-acting benzodiazepine ataxia.',
          medications: 'Two high-risk medications flagged on 2023 AGS Beers Criteria®.',
          multiComplexity: 'Rockwood CFS Level 3 (Managing Well) with preventable fall hazard.',
          mattersMost: 'Preserving ambulatory independence and sharp cognitive clarity.'
        },
        beersFlags: [
          {
            medication: 'Diphenhydramine',
            category: 'High Anticholinergic Burden',
            action: 'Discontinue for sleep. Substitute sleep hygiene and photic circadian entrainment.'
          },
          {
            medication: 'Diazepam',
            category: 'Long-Acting Benzodiazepine (Fall / Ataxia Risk)',
            action: 'Initiate slow supervised taper. Substitute non-sedating CBT-I or buspirone if needed.'
          }
        ]
      }, null, 2),
      chosen: 'Identifies both Beers Criteria flags (diphenhydramine anticholinergic risk and diazepam long-acting fall risk), structures review using the Geriatric 5Ms, and provides safer non-pharmacological de-prescribing alternatives.',
      rejected: 'Increases diphenhydramine dose to 50mg for better sleep and adds zolpidem without addressing fall risk or Beers Criteria.'
    },
    // 17. Food-as-Medicine (FAM) & Microbiome SCFA Butyrate Synthesis
    {
      paradigm: 'food_as_medicine_scfa',
      instruction: 'Formulate an evidence-grounded Food-as-Medicine produce prescription and microbiome SCFA protocol for a patient with subclinical inflammation (hs-CRP 2.8 mg/L).',
      input: JSON.stringify({
        clinicalGoal: 'Lower systemic CRP and optimize colonic butyrate production',
        dietaryPreference: 'Mediterranean / Plant-Slant'
      }, null, 2),
      output: JSON.stringify({
        dietaryPattern: 'MIND / Mediterranean-DASH Hybrid',
        producePrescriptions: [
          {
            food: 'Cooked & Cooled Purple Potatoes / Rolled Oats',
            bioactive: 'Type-3 Resistant Starch & Beta-Glucan',
            mechanism: 'Colonic fermentation by Faecalibacterium prausnitzii into anti-inflammatory butyrate (SCFA).',
            culinaryTip: 'Cook thoroughly, refrigerate 12+ hours to induce starch retrogradation before gentle reheating.'
          },
          {
            food: 'Wild Blueberries & Blackberries',
            bioactive: 'Anthocyanins & Delphinidin',
            mechanism: 'Suppresses NF-kB signaling and microglial inflammatory cytokines.',
            culinaryTip: 'Pair with raw walnuts for lipid-assisted bioabsorption.'
          }
        ],
        plantDiversityTarget: 'Aim for ≥ 30 distinct plant species/week across alliums, cruciferous, legumes, berries, and seeds.'
      }, null, 2),
      chosen: 'Synthesizes targeted prebiotic resistant starches for colonic SCFA butyrate fermentation, provides actionable retrogradation culinary tips, and sets the 30+ plant species diversity benchmark.',
      rejected: 'Prescribes generic low-calorie diet pills and artificial meal replacement shakes without addressing microbiome diversity or butyrate synthesis.'
    },
    // 18. Cardiology & Hemodynamics (AHA/ACC GDMT & ECG Vector Triangulation)
    {
      paradigm: 'cardiology_ecg_hemodynamics',
      instruction: 'Evaluate a 66-year-old patient with new HFrEF (LVEF 32%, NYHA Class III, BP 118/74, eGFR 58 mL/min, K+ 4.4 mEq/L) and initiate 4-pillar GDMT.',
      input: JSON.stringify({
        age: 66,
        lvef: '32%',
        nyhaClass: 'III',
        bp: '118/74 mmHg',
        hr: '78 bpm (sinus rhythm)',
        serumK: '4.4 mEq/L',
        eGfr: '58 mL/min/1.73m2',
        currentMeds: ['Furosemide 20mg PO QD']
      }, null, 2),
      output: JSON.stringify({
        clinicalStratification: 'Stage C HFrEF with volume stabilization on loop diuretic.',
        fourPillarGdmtInitiation: [
          {
            pillar: 'ARNI (Angiotensin Receptor-Neprilysin Inhibitor)',
            agent: 'Sacubitril/Valsartan 24/26 mg (50 mg) PO BID',
            rationale: 'Class 1A mortality reduction over ACEi. Initiated at low starting dose given baseline SBP 118 mmHg.'
          },
          {
            pillar: 'Evidence-Based Beta-Blocker',
            agent: 'Metoprolol Succinate ER 25 mg PO QD or Carvedilol 3.125 mg PO BID',
            rationale: 'Class 1A neurohormonal blockade. Titrate every 2 weeks to target heart rate 60-70 bpm.'
          },
          {
            pillar: 'Mineralocorticoid Receptor Antagonist (MRA)',
            agent: 'Spironolactone 12.5-25 mg PO QD',
            rationale: 'Class 1A anti-fibrotic remodeling. Serum K+ (4.4) and eGFR (58) satisfy strict safety thresholds (K < 5.0, eGFR > 30).'
          },
          {
            pillar: 'SGLT2 Inhibitor',
            agent: 'Dapagliflozin 10 mg or Empagliflozin 10 mg PO QD',
            rationale: 'Class 1A cardiorenal metabolic unburdening irrespective of glycemic status.'
          }
        ],
        safetyMonitoring: 'Schedule comprehensive metabolic panel (serum K+ and creatinine) in 7-14 days post-initiation.'
      }, null, 2),
      chosen: 'Implements full 4-pillar AHA/ACC GDMT (ARNI + Beta-blocker + MRA + SGLT2i), checks potassium/renal safety thresholds, and schedules 14-day lab surveillance.',
      rejected: 'Prescribes high-dose diltiazem (calcium channel blocker contraindicated in HFrEF) and doubles furosemide without neurohormonal GDMT.'
    },
    // 19. Oncology & Molecular Tumor Board (NGS Variant & NCCN Target Matching)
    {
      paradigm: 'oncology_molecular_tumor_board',
      instruction: 'Interpret comprehensive NGS genomic panel for stage IV non-small cell lung adenocarcinoma and correlate actionable kinase mutations.',
      input: JSON.stringify({
        histology: 'Lung Adenocarcinoma, Stage IV (Hepatic & Bone Metastases)',
        ngsPanel: {
          egfr: 'Exon 19 deletion (p.E746_A750del) detected',
          t790m: 'Negative',
          c797s: 'Negative',
          alk: 'Negative (IHC 0)',
          ros1: 'Negative (FISH)',
          pdl1Tps: '15%'
        },
        ecogPerformanceStatus: 1
      }, null, 2),
      output: JSON.stringify({
        molecularClassification: 'EGFR-Mutant (Sensitizing Exon 19 Deletion) Metastatic Lung Adenocarcinoma.',
        nccnGuidelineTherapy: {
          firstLineStandard: 'Osimertinib 80 mg PO once daily (Third-generation CNS-penetrant EGFR TKI, Category 1 recommendation).',
          rationale: 'Superior progression-free survival (PFS) and overall survival (OS) compared to first-generation gefitinib/erlotinib with robust blood-brain barrier penetration.'
        },
        immunotherapyAdvisory: 'Withhold single-agent immune checkpoint inhibitors (anti-PD-1/PD-L1) despite PD-L1 TPS 15% due to lack of efficacy in classical EGFR driver mutations and severe pneumonitis risk when followed by TKI.',
        surveillancePlan: 'Serial cell-free ctDNA liquid biopsy at progression to detect emergent C797S or MET amplification resistance mechanisms.'
      }, null, 2),
      chosen: 'Selects third-generation osimertinib (NCCN Category 1), explicitly warns against checkpoint immunotherapy monotherapy in EGFR drivers, and outlines liquid biopsy ctDNA resistance tracking.',
      rejected: 'Recommends generic platinum chemotherapy doublet plus pembrolizumab without targeting the sensitizing EGFR Exon 19 mutation.'
    },
    // 20. Nephrology & Renal Clearance (KDIGO CKD Staging & Hyperkalemia Algorithm)
    {
      paradigm: 'nephrology_renal_clearance',
      instruction: 'Manage acute hyperkalemia (K+ 6.8 mEq/L with peaked T-waves on ECG) in a CKD Stage 4 patient with strict safety sequence.',
      input: JSON.stringify({
        serumPotassium: '6.8 mEq/L',
        ecgFindings: 'Tall peaked symmetric T-waves in V2-V5, PR interval 210 ms',
        eGfr: '22 mL/min/1.73m2 (CKD Stage 4)',
        activeMeds: ['Lisinopril 20mg QD', 'Spironolactone 25mg QD']
      }, null, 2),
      output: JSON.stringify({
        triageAcuity: 'STAT_HYPERKALEMIC_EMERGENCY',
        threePhaseResuscitation: {
          phase1_membraneStabilization: 'Calcium gluconate 10% 1,000 mg (10 mL) IV over 2-3 minutes under continuous cardiac monitoring (stabilizes cardiomyocyte resting potential; repeats in 5-10 min if ECG abnormalities persist).',
          phase2_intracellularShifting: 'Regular Insulin 10 Units IV bolus combined with 50 mL Dextrose 50% (D50W 25g) to prevent hypoglycemia + Albuterol 10-20 mg nebulized over 15 min.',
          phase3_elimination: 'Sodium zirconium cyclosilicate (Lokelma) 10g PO TID or Loop Diuretic (Furosemide IV) if volume overloaded; prepare hemodialysis access if refractory.'
        },
        medicationHold: 'Immediately discontinue Lisinopril and Spironolactone until potassium normalizes (< 5.0 mEq/L).'
      }, null, 2),
      chosen: 'Executes the standard 3-phase hyperkalemia protocol (Calcium gluconate membrane stabilization FIRST $\to$ Insulin/D50 shifting $\to$ GI/renal excretion), holds RAAS inhibitors, and monitors continuous ECG rhythm.',
      rejected: 'Gives oral sodium polystyrene sulfonate (Kayexalate) as sole emergency therapy without cardiac membrane stabilization or insulin shifting.'
    },
    // 21. Emergency Medicine & STAT Resuscitation (ACLS Shock Index & Sepsis Bundle)
    {
      paradigm: 'emergency_stat_resuscitation',
      instruction: 'Execute resuscitation protocol for a trauma patient presenting with hemorrhagic shock (HR 134, SBP 78, Shock Index 1.72).',
      input: JSON.stringify({
        mechanism: 'High-speed motor vehicle collision',
        vitals: 'HR 134 bpm, BP 78/46 mmHg, RR 28, SpO2 93% on room air',
        shockIndex: 1.72,
        fastUltrasound: 'Positive fluid in Morison’s pouch and splenorenal recess'
      }, null, 2),
      output: JSON.stringify({
        triageCategory: 'CLASS_IV_HEMORRHAGIC_SHOCK',
        immediateActions: [
          'Activate Institutional Massive Transfusion Protocol (MTP) with 1:1:1 balanced ratio (Packed Red Blood Cells : Fresh Frozen Plasma : Platelets).',
          'Administer Tranexamic Acid (TXA) 1 g IV over 10 min (within 3-hour trauma injury window per CRASH-2), followed by 1 g IV infusion over 8 hours.',
          'Permissive hypotension target (MAP 55-65 mmHg / SBP ~90 mmHg) to prevent clot disruption until definitive surgical hemostasis.',
          'Initiate active core warming (Bair Hugger / warm fluid infusor) to prevent lethal trauma triad (coagulopathy, hypothermia, acidosis).'
        ],
        disposition: 'Immediate STAT transfer to trauma operating suite for exploratory laparotomy.'
      }, null, 2),
      chosen: 'Calculates high Shock Index (1.72), activates balanced 1:1:1 MTP, administers TXA within 3 hours, enforces permissive hypotension, and dispatches to OR.',
      rejected: 'Infuses 4 liters of cold normal saline bolus without blood products and delays operative transfer.'
    },
    // 22. Psychiatry & Psychopharmacology (C-SSRS Crisis & Washout Protocol)
    {
      paradigm: 'psychiatry_psychopharm_crisis',
      instruction: 'Formulate safe psychopharmacological transition protocol from high-dose Fluoxetine (Prozac) to Phenelzine (Nardil / MAOI) while preventing Serotonin Syndrome.',
      input: JSON.stringify({
        currentMed: 'Fluoxetine 60 mg PO QD (taken for 8 months)',
        targetMed: 'Phenelzine (MAO Inhibitor)',
        indication: 'Treatment-Resistant Major Depressive Disorder',
        lastDoseDate: 'Today'
      }, null, 2),
      output: JSON.stringify({
        safetyDirective: 'STRICT_WASHOUT_INTERVAL_MANDATE',
        pharmacokineticRationale: 'Fluoxetine and its active metabolite norfluoxetine have an exceptionally prolonged elimination half-life (up to 16 days). Combining or overlapping with an MAOI precipitates potentially fatal Serotonin Toxicity (hyperthermia, autonomic instability, neuromuscular clonus).',
        protocolSteps: [
          'Step 1: Discontinue Fluoxetine 60 mg immediately.',
          'Step 2: Enforce mandatory 5-WEEK (35-DAY) complete washout period before initiating Phenelzine.',
          'Step 3: During washout, bridge supportive psychotherapy, daily C-SSRS suicide safety checks, and non-serotonergic anxiolytics if needed.',
          'Step 4: Educate patient on strict tyramine-restricted diet (aged cheeses, cured meats, draught beer) prior to MAOI start.'
        ]
      }, null, 2),
      chosen: 'Enforces the mandatory 5-week washout interval between fluoxetine and an MAOI, explains norfluoxetine half-life pharmacology, and mandates tyramine dietary counseling.',
      rejected: 'Starts phenelzine the next day or recommends a brief 3-day washout, precipitating lethal Serotonin Syndrome.'
    },
    // 23. Obstetrics / Gynecology & Teratology (ACOG Preeclampsia & Briggs Teratology)
    {
      paradigm: 'obgyn_fetal_maternal_teratology',
      instruction: 'Manage acute severe-range hypertension in a 34-week pregnant patient with preeclampsia with severe features.',
      input: JSON.stringify({
        gestationalAge: '34 weeks 2 days',
        bloodPressure: '168/112 mmHg (confirmed on repeat in 15 min)',
        symptoms: 'Persistent frontal headache, visual scotomata, 3+ brisk patellar reflexes with clonus',
        platelets: '142,000 / uL',
        astAlt: 'Normal'
      }, null, 2),
      output: JSON.stringify({
        acogDiagnosis: 'Preeclampsia with Severe Features (Severe-Range Hypertension & Neurological Symptoms).',
        urgentPharmacotherapy: [
          {
            intervention: 'Maternal Seizure Prophylaxis',
            regimen: 'Magnesium Sulfate 4-6 g IV loading dose over 15-20 min, followed by 1-2 g/hour continuous maintenance infusion.',
            monitoring: 'Hourly patellar reflexes, respiratory rate (hold if RR < 12), and urine output (keep > 30 mL/hr). Ensure Calcium Gluconate at bedside as antidote.'
          },
          {
            intervention: 'Emergent Antihypertensive Therapy (Goal SBP 140-150 / DBP 90-100 to prevent maternal stroke)',
            regimen: 'Labetalol 20 mg IV bolus over 2 min (repeat with 40 mg, then 80 mg every 10-20 min if SBP ≥ 160 or DBP ≥ 110) OR Hydralazine 5-10 mg IV.'
          }
        ],
        fetalMaternalDisposition: 'Betamethasone 12 mg IM (first dose for fetal lung maturity); transfer to labor & delivery for continuous electronic fetal monitoring.'
      }, null, 2),
      chosen: 'Initiates immediate Magnesium Sulfate seizure prophylaxis with Calcium Gluconate antidote on standby, administers IV Labetalol for severe-range BP, and gives antenatal corticosteroids for fetal lung maturity.',
      rejected: 'Prescribes oral ACE inhibitors (fetal renal teratogen) and discharges home with bed rest.'
    },
    // 24. Endocrinology & Advanced Diabetes / Pumps (CGM AGP & DKA Protocol)
    {
      paradigm: 'endocrinology_glycemic_pump',
      instruction: 'Analyze Continuous Glucose Monitoring (CGM) Ambulatory Glucose Profile (AGP) and optimize Automated Insulin Delivery (AID) settings.',
      input: JSON.stringify({
        cgmMetrics: {
          timeInRange70_180: '54% (Target > 70%)',
          timeBelowRangeUnder70: '6.2% (Target < 4%)',
          timeBelow54VeryLow: '2.1% (Target < 1%)',
          timeAboveRange180_250: '28%',
          timeAbove250VeryHigh: '11.8%',
          glucoseManagementIndicatorGmi: '7.6%',
          coefficientOfVariationCv: '41.2% (Target ≤ 36%)'
        },
        hypoglycemiaPatterns: 'Frequent 2:00 AM - 4:00 AM nocturnal hypoglycemic troughs'
      }, null, 2),
      output: JSON.stringify({
        agpInterpretation: 'High Glycemic Variability (CV 41.2%) with excessive nocturnal hypoglycemia (TBR 6.2%) compromising patient safety.',
        insulinOptimizationPlan: [
          {
            priority: 'SAFETY FIRST: Eliminate Nocturnal Hypoglycemia',
            action: 'Reduce overnight basal rate (00:00 - 05:00) by 15-20% on automated insulin delivery system.'
          },
          {
            priority: 'Address Postprandial Evening Excursions',
            action: 'Advance pre-bolus timing from 0 min to 15 min prior to dinner to blount postprandial glucose spike, reducing late rebound hypoglycemia.'
          },
          {
            priority: 'Insulin-to-Carbohydrate Ratio (ICR)',
            action: 'Maintain current breakfast/lunch ICR (1:10) but adjust dinner ICR from 1:8 to 1:10 to prevent dinner over-bolusing.'
          }
        ]
      }, null, 2),
      chosen: 'Prioritizes elimination of nocturnal hypoglycemia (TBR 6.2%) by reducing overnight basal rate by 15-20%, reinforces pre-bolus timing, and brings CV below 36%.',
      rejected: 'Increases total daily insulin dose by 20% across all hours, drastically worsening life-threatening nighttime hypoglycemia.'
    },
    // 25. Infectious Disease & Antimicrobial Stewardship (IDSA Antibiogram Step-Down)
    {
      paradigm: 'id_antimicrobial_stewardship',
      instruction: 'Optimize antimicrobial regimen for a hospitalized patient with Community-Acquired Pneumonia (CAP) following blood and sputum culture finalization.',
      input: JSON.stringify({
        initialEmpiricRegimen: 'Vancomycin 15 mg/kg IV q12h + Cefepime 2 g IV q8h (Day 3 of therapy)',
        microbiologyResults: {
          sputumCulture: 'Heavy growth of Streptococcus pneumoniae (Pan-susceptible to Penicillin, Ceftriaxone, Levofloxacin)',
          bloodCultures: 'No growth at 48 hours',
          mrsaNasalPcr: 'Negative'
        },
        clinicalStatus: 'Afebrile for 24 hours, RR 16, SpO2 96% on room air, tolerating oral diet'
      }, null, 2),
      output: JSON.stringify({
        stewardshipAssessment: 'Microbiologically confirmed S. pneumoniae CAP with clinical stability; candidate for immediate de-escalation and oral step-down.',
        stewardshipActions: [
          {
            action: 'De-escalate & Discontinue Vancomycin',
            rationale: 'Negative MRSA nasal screen (high negative predictive value > 98%) and documented pneumococcal etiology.'
          },
          {
            action: 'Discontinue Cefepime',
            rationale: 'Antipseudomonal broad-spectrum coverage unnecessary for pan-susceptible S. pneumoniae.'
          },
          {
            action: 'Step-Down to Targeted Oral Therapy',
            regimen: 'Amoxicillin 1,000 mg PO TID OR Ceftriaxone 1 g IV QD if oral absorption compromised.',
            totalDuration: '5 total days (Day 1-3 IV + Day 4-5 PO) per IDSA/ATS guidelines given clinical stability.'
          }
        ]
      }, null, 2),
      chosen: 'De-escalates from Vancomycin/Cefepime to targeted oral Amoxicillin, utilizes MRSA nasal swab NPV, and bounds total therapy to 5 evidence-based days.',
      rejected: 'Continues broad-spectrum Vancomycin and Cefepime for 14 full days despite negative cultures and MRSA swab.'
    },
    // 26. Neurology & Acute Stroke Care (NIHSS & Thrombolytic Checklist)
    {
      paradigm: 'neurology_acute_stroke',
      instruction: 'Evaluate IV thrombolysis (Tenecteplase / TNK) eligibility for a 68-year-old patient with acute left hemiparesis and facial droop.',
      input: JSON.stringify({
        symptomOnset: '75 minutes ago (witnessed last known normal)',
        nihssScore: 11,
        nonContrastHeadCt: 'No acute intracranial hemorrhage, ASPECTS score 10',
        bloodPressure: '172/96 mmHg',
        bloodGlucose: '138 mg/dL',
        inr: '1.0 (no anticoagulant use)',
        platelets: '220,000 / uL',
        surgicalHistory: 'No major surgery in past 3 months'
      }, null, 2),
      output: JSON.stringify({
        strokeProtocolAcuity: 'CODE_STROKE_THROMBOLYSIS_CANDIDATE',
        eligibilityChecklist: {
          timeWindow: 'Within 4.5-hour golden window (Onset 75 min ago)',
          neuroimaging: 'CT head negative for hemorrhage / early infarct signs',
          bloodPressure: 'BP 172/96 satisfies safety threshold (< 185/110 mmHg)',
          coagulation: 'Normal INR (1.0) and platelets (> 100k)'
        },
        therapeuticOrder: {
          agent: 'Tenecteplase (TNK-tPA) 0.25 mg/kg IV single bolus over 5 seconds (max 25 mg).',
          concurrentOrders: 'STAT CT Angiography (CTA) head/neck to evaluate for Large Vessel Occlusion (LVO) candidate for Endovascular Thrombectomy (EVT).',
          postAdministrationMonitoring: 'Neuro checks and BP monitoring q15min x 2 hours; maintain BP < 180/105 mmHg.'
        }
      }, null, 2),
      chosen: 'Confirms thrombolytic eligibility within 4.5 hours, orders Tenecteplase bolus (0.25 mg/kg), initiates CTA for Large Vessel Occlusion / thrombectomy, and enforces strict post-TNK BP limits.',
      rejected: 'Delays thrombolysis by ordering an elective MRI brain and gives aspirin immediately before thrombolytic administration.'
    },
    // 27. Rheumatology & Autoimmune Serology (ACR/EULAR Triangulation)
    {
      paradigm: 'rheumatology_autoimmune_serology',
      instruction: 'Triangulate complex autoimmune serology panel with clinical symptoms for a 28-year-old female with symmetric polyarthritis, malar rash, and photosensitivity.',
      input: JSON.stringify({
        symptoms: 'Symmetric PIP/MCP joint tenderness x 8 weeks, photosensitive facial erythema sparing nasolabial folds, oral mucosal ulcers',
        labResults: {
          anaIFA: 'Positive 1:640 (Homogeneous / Rim pattern)',
          antiDsDna: 'Positive 88 IU/mL (Reference < 10)',
          antiSmith: 'Positive',
          antiRoSsa: 'Negative',
          c3Complement: '58 mg/dL (Low, Ref 90-180)',
          c4Complement: '8 mg/dL (Low, Ref 16-47)',
          urinalysis: 'Protein 2+ (UACR 450 mg/g), 8-10 RBCs/HPF (no casts)'
        }
      }, null, 2),
      output: JSON.stringify({
        diagnosticSynthesis: 'Systemic Lupus Erythematosus (SLE) satisfying 2019 EULAR/ACR Classification Criteria (> 10 points: Joint involvement, malar rash, mucosal ulcers, anti-dsDNA, anti-Smith, hypocomplementemia).',
        renalInvolvement: 'Probable active Lupus Nephritis (proteinuria + active sediment microhematuria).',
        immediateManagement: [
          {
            pillar: 'Baseline Disease-Modifying Therapy',
            agent: 'Hydroxychloroquine (HCQ) 5 mg/kg actual body weight PO QD (reduces flares, prevents organ damage, improves survival).',
            baselineTesting: 'Baseline ophthalmology examination (spectral-domain OCT and visual field) for retinal safety.'
          },
          {
            pillar: 'Renal Evaluation',
            action: 'STAT Nephrology consultation for ultrasound-guided percutaneous renal biopsy to classify ISN/RPS lupus nephritis class (Class I-VI).'
          },
          {
            pillar: 'Immunosuppressive Induction',
            agent: 'Pulse methylprednisolone followed by Mycophenolate Mofetil (MMF) or Cyclophosphamide pending biopsy results.'
          }
        ]
      }, null, 2),
      chosen: 'Applies 2019 EULAR/ACR SLE criteria, orders gold-standard Hydroxychloroquine at safe 5 mg/kg actual weight dosing with baseline retinal OCT, and triggers STAT renal biopsy for active nephritis.',
      rejected: 'Diagnoses simple osteoarthritis, prescribes NSAIDs only, and fails to screen for lupus nephritis or initiate hydroxychloroquine.'
    }
  ];
}

export function exportDatasetToJsonl(outputPath) {
  const dataset = generateAllParadigmsDataset();
  const targetDir = path.join(process.cwd(), 'scratch');
  if (!fs.existsSync(targetDir)) {
    fs.mkdirSync(targetDir, { recursive: true });
  }

  const file = outputPath || path.join(targetDir, 'pocketgull_15paradigms_dataset.jsonl');
  const content = dataset.map(rec => JSON.stringify(rec)).join('\n');
  fs.writeFileSync(file, content, 'utf-8');

  console.log(`✅ Successfully exported ${dataset.length} fine-tuning records across all 15 paradigms to: ${file}`);
  return file;
}

// CLI entrypoint
exportDatasetToJsonl();
